Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$108.99 USD
-1.77 (-1.60%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $108.98 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
JAZZ 108.99 -1.77(-1.60%)
Will JAZZ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Jazz (JAZZ) Up 1.1% Since Last Earnings Report?
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Other News for JAZZ
Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Truist Financial
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Jazz Pharmaceuticals presents updated Phase 2 data for zanidatamab
Stock moves reflect downgrade for US economic growth outlook - Goldman